+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the safety and tolerability of single and multiple intravenous doses of GIGA-2339 in adults with chronic Hepatitis B Virus HBV infection. This Phase 1 randomized, double-blind, placebo-controlled study aims to understand how GIGA-2339 behaves in the body and monitor any side effects in participants with stable HBV infection. Participants will receive either a single ascending dose or multiple ascending doses of GIGA-2339 or placebo through intravenous infusion. In Part 1, they get a single infusion on Day 1, and in Part 2, they receive multiple infusions every 4 weeks at doses determined from Part 1. The study compares these treatments to placebo to evaluate safety and pharmacokinetics. During the study, participants undergo regular blood tests to measure drug levels and monitor safety up to Day 105 for the single dose and Day 245 for multiple doses. Researchers record any adverse events and serious side effects. The study lasts until November 2028, with ongoing assessments of participants responses and tolerability throughout the dosing and follow-up periods.

Age: 18Years +All GendersPhase 1
20 locations
R

Actively Recruiting

Researchers are evaluating the effects of Levagen supplementation on symptoms of diabetic peripheral neuropathy DPN in adults aged 18 to 75 years with this condition. This Phase 2 clinical trial aims to determine how Levagen impacts neuropathic pain and other related health measures over a 12-week period. The study compares Levagen to a placebo to assess its potential benefits for people with DPN. Participants will be randomly assigned to take either Levagen capsules or placebo capsules twice daily with water after food. Each Levagen capsule contains 150 mg of palmitoylethanolamide PEA, totaling 300 mg daily. The placebo capsules contain microcrystalline cellulose. The treatment period lasts 12 weeks, during which participants attend remote visits every 3 weeks and visit a local pathology center for blood draws. During the study, participants will be monitored for changes in neuropathic pain severity, symptom inventories, safety through adverse event reporting and lab markers, vital signs, sleep quality, mood, glycemic control, body measurements, and rescue medication use. Assessments occur from baseline through week 12. The trial includes detailed safety and efficacy measurements to understand the effects of Levagen on diabetic peripheral neuropathy symptoms.

Age: 18Years - 75YearsAll GendersPhase 2
1 location
E

Actively Recruiting

Researchers are evaluating a new way to deliver treatment using the ECAP-controlled closed-loop spinal cord stimulation SCS system called the Evoke System. This study focuses on patients who experience chronic pain in the trunk andor limbs. The goal is to test and assess new software and hardware features that may improve how the Evoke System delivers treatment. Participants will use the Evoke Spinal Cord Stimulation System, which measures electrical activity called evoked compound action potentials ECAPs. The device automatically adjusts the stimulation current to keep the ECAP amplitude consistent. This study involves a single group of participants using this novel device and will continue through to study completion, which may last up to two years. During the study, participants will be monitored for changes in ECAPs measured by the Evoke System. Researchers will evaluate these changes over the course of the study to understand how the device functions with the new features. Participants will need to provide informed consent and comply with study requirements while using the device. The total participation time can last up to two years, with regular assessments conducted throughout this period.

Age: 18Years +All GendersPhase Not Applicable
25 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how well supplements with and without absorption-enhancing technology are absorbed in healthy adults aged 18 and older. This study focuses on vitamin D3 and omega-3 supplements. It aims to compare the absorption levels of these nutrients using different formulations in a randomized, parallel-group design. Participants are divided into groups receiving either a single dose of omega-3 or daily vitamin D3 supplements. Part A includes two groups receiving a single 315mg dose of omega-3 and two groups taking 1000IU of vitamin D3 daily for 7 days. Part B involves two groups taking 1000IU of vitamin D3 daily for 6 weeks. Each group receives either an enhanced formulation or a comparator version. During the study, participants will have scheduled blood collections to measure nutrient absorption over time, including up to 7 days for vitamin D3 and up to 6 weeks in the extended phase. Researchers will monitor safety, tolerability, and demographic data. The primary outcomes focus on serumplasma absorption measured by area under the curve AUC for each supplement. The total study duration varies depending on the group assignment, with close monitoring throughout.

Age: 18Years +All GendersPhase 4
1 location